Pfizer, Moderna Stocks Down Over 30% in 2022 But New Drug Launches May Catalyze Growth
-
Pfizer stock is down 34% over the past year but has growth potential from new drug approvals and its acquisition of Seagen to expand in oncology
-
Moderna stock is down 35% over the past year but has an upcoming FDA decision on its RSV vaccine and other pipeline products that could drive future growth
-
Both Pfizer and Moderna saw declining demand for their COVID-19 products but have opportunities in other therapeutic areas
-
Pfizer is trading at 12x forward earnings, presenting a buying opportunity for this transitioning business
-
Moderna projects returning to organic sales growth in 2025 based on the success of its RSV vaccine and other late-stage pipelines